Comparative Pharmacology
Head-to-head clinical analysis: UNASYN versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNASYN versus VEETIDS 500.
UNASYN vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic